CD26 is an antigen with key role in T-cell biology and is expressed on selected subsets of aggressive T-cell malignancies. To elucidate the role of CD26 in tumor behavior, we examine the effect of CD26 depletion by small interfering RNA transfection of T-anaplastic large cell lymphoma Karpas 299. We show that the resultant CD26-depleted clones lose the ability to adhere to fibronectin and collagen I. Because antiintegrin B 1 blocking antibodies also prevent binding of Karpas 299 to fibronectin and collagen I, we then evaluate the CD26-integrin B 1 association. CD26 depletion does not decrease integrin B 1 expression but leads to dephosphorylation of both integrin B 1 and p38 mitogen-activated protein kinase (MAPK). Moreover, our data showing that the p38MAPK inhibitor SB203580 dephosphorylates integrin B 1 and that binding of the anti-CD26 antibody 202.36 dephosphorylates both p38MAPK and integrin B 1 on Karpas 299, leading to loss of cell adhesion to the extracellular matrix, indicate that CD26 mediates cell adhesion through p38MAPK-dependent phosphorylation of integrin B 1 . Finally, in vivo experiments show that depletion of CD26 is associated with loss of tumorigenicity and greater survival. Our findings hence suggest that CD26 plays an important role in tumor development and may be a novel therapeutic target for selected neoplasms. (Cancer Res 2005; 65(15): 6950-6) 
Introduction
CD26/dipeptidyl peptidase IV is a 110-kDa cell surface glycoprotein that belongs to the serine protease family and is expressed on a variety of tissues, including T lymphocytes, endothelial cells, and epithelial cells. It is composed of a short cytoplasmic domain, a transmembrane region, and an extracellular domain with dipeptidyl peptidase IV activity, which selectively removes the NH 2 -terminal dipeptide from polypeptides containing either a proline or an alanine at the penultimate residue. This enzymatic activity seems to regulate the effect of several crucial cytokines and chemokines (1) . Work over the past decade has shown CD26 to have an important role in T-cell biology both as a marker of T-cell activation and as a structure associated with key molecules and signaling pathways (2) (3) (4) (5) .
Although the role of CD26 in the regulation of normal T-cell physiology has been well characterized, its involvement in tumor biology is still unclear, although early data suggested that it may have a role in the development of selected neoplasms. Studies of patient samples showed that CD26 is highly expressed on lung adenocarcinoma, thyroid carcinoma, and B-cell chronic lymphocytic leukemia (6) (7) (8) . Meanwhile, CD26 is a marker of aggressive disease for selected subsets of T-cell non-Hodgkin's lymphomas/ leukemias. Carbone et al. showed that CD26 expression is restricted to such aggressive types of T-cell malignancies as T-lymphoblastic lymphomas (T-LBL), T-acute lymphoblastic leukemias (T-ALL), and T-anaplastic large cell lymphomas (T-ALCL). Furthermore, multivariate analysis indicated that the expression of CD26 on T-LBL/T-ALL tumor cells is associated with a worse outcome compared with CD26-negative T-LBL/T-ALL tumors (9) . Similarly, we showed recently that CD26 expression is a marker of poor prognosis for T-large granular lymphocyte lymphoproliferative disorder (10) . Although these findings suggested that CD26 may regulate the malignant behavior of selected tumors, the exact mechanisms involved in the role of CD26 in tumor biology remain to be elucidated.
In this article, we evaluate the role of CD26 in tumor biology by depleting the expression of CD26 on the T-ALCL cell line Karpas 299 with the small interfering RNA (siRNA) technique. We show that CD26 mediates cell adhesion to the extracellular matrix (ECM) proteins fibronectin and collagen I through p38 mitogenactivated protein kinase (MAPK)-dependent phosphorylation of integrin h 1 . We also show that CD26 expression regulates topoisomerase IIa level and tumor sensitivity to the topoisomerase II inhibitor doxorubicin. Importantly, loss of CD26 expression on Karpas 299 cells results in decreased tumorigenicity and improved survival in a severe combined immunodeficient (SCID) mouse animal model, hence suggesting that targeting CD26 may be an effective therapeutic approach for selected CD26-positive T-cell malignancies.
Materials and Methods
Reagents. All culture plates and dishes were purchased from Falcon Plastics (Oxnard, CA). Mouse anti-integrin h 1 antibody (P4C10) was from Chemicon (Temecula, CA). Mouse anti-integrin h 1 antibody (4B4) and isotypic control mouse IgG were from Beckman Coulter (Miami, FL). Mouse anti-CD26 antibody (202.36) was from Santa Cruz (Santa Cruz, CA). Mouse anti-CD26 antibodies (1F7 and 5F8) were prepared as described previously (11) . Specific inhibitors against p38MAPK SB203580 was from Biomol (Plymouth, Meeting, PA). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was from Sigma (St. Louis, MO). Doxorubicin was from Calbiochem (La Jolla, CA).
Cell culture. The human T-ALCL cell line Karpas 299 was supplied by American Type Culture Collection (Manassas, VA) and maintained in RPMI 1640 (Sigma) with 10% heat-inactivated FCS (Sigma) and antibiotics (100 IU/mL penicillin and 100 Ag/mL streptomycin) at 37jC in a humidified atmosphere containing 5% CO 2 .
Depletion of CD26. The expression of CD26 was suppressed by Knockout RNAi System (Clontech, Palo Alto, CA) as described previously (12) . Briefly, the target sequence ATCATGCATGCAATCAAC, which corresponds to the nucleotide sequence from 1,768 to 1,785 of CD26 cDNA (accession no. NM_001935), was first determined using siDESIGN program at Dharmacon siDESIGN Center (http://design.dharmacon.com/). Complementary oligonucleotides encoding siRNA were then designed and ligated into vector RNAi-Ready pSIREN-RetroQ (Clontech) according to the manufacturer's instructions. Oligonucleotides encoding missense siRNA, in which the target sequence was replaced with the missense sequence ATCTTGCAAGCAAACAAC, were also ligated into the vector as controls. For the retroviral packaging, these constructs were cotransfected with p10A1 (Clontech) into GP2-293 cells (Clontech) using LipofectAMINE reagent (Invitrogen, Carlsbad, CA). The supernatants containing retrovirus were collected 72 hours after the transfection. Then, this supernatant was added to culture medium of Karpas 299 cells, which was supplemented with 8 Ag/mL polybrene (Sigma). After 3 days of incubation, the cells were cultured with 0.4 Ag/mL puromycin (Clontech) to eliminate nontransfected cells. Isolated clones were obtained by the standard limiting dilution method.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromideassay. The cells were cultured with 100 or 300 AL medium in each well of a 96-or 24-well plate, respectively. To quantify the total number of cells, a quarter volume of the MTT solution, PBS containing 5 mg/mL MTT, was added to the culture medium. To quantify the number of adhesive cells, the culture medium, in which nonadhesive cells were floating after the plates were shaken orbitally several times, was discarded. Then, the same volume of fresh medium with a quarter volume of MTT solution was added to the remaining adhesive cells. In both quantifications, the cells were cultured for 2 hours and added with the same volume of lysis buffer as described previously (13) . After overnight incubation at 37jC, the absorbance of dissolved blue formazan was measured at 570 nm in spectrophotometer lQuant (Bio-Tek, Winooski, VT) with KC junior software.
Flow cytometry. The cells were collected, washed twice with PBS, and resuspended in 0.5 mL fluorescence-activated cell sorting buffer, PBS containing 0.5 mmol/L EDTA and 1% (w/v) bovine serum albumin (Sigma). Then, the cells were incubated on ice for 30 minutes with anti-CD26 (Caltag, Burlingame, CA) or anti-integrin h 1 (4B4) mouse monoclonal antibody. Isotypic mouse IgG was used as a control. Surface antigens detected by these antibodies were visualized with FITC-conjugated anti-mouse IgG antibody (Pierce, Rockford, IL), followed by the use of FACSCalibur (Becton Dickinson, San Jose, CA) with CellQuest software.
Western blotting. Cells (1 Â 10 7 ) were collected, washed twice with PBS, and resuspended in 0.3 mL lysis buffer [1% SDS, 10 mmol/L Tris-HCl (pH 7.4), 10 Ag/mL leupeptin, 10 Ag/mL aprotinin, 2 mmol/L phenylmethylsulfonyl fluoride] and then boiled for 5 minutes. After passage through a 20-gauge needle 10 times and centrifugation at 15,000 rpm for 20 minutes, the aliquot was boiled again with a standard 4Â SDS loading buffer containing 15% (v/v) 2-mercaptoethanol for 5 minutes; 10 AL of which were then subjected to SDS-polyacrylamide gel for electrophoresis followed by the transfer to Immobilon membrane (Millipore, Bedford, MA). The membrane was hybridized with goat anti-CD26/dipeptidyl peptidase IV (R&D, Minneapolis, MN), mouse anti-topoisomerase IIa (Ki-S1, Chemicon), mouse anti-phosphotopoisomerase IIa Thr 1342 (3D4, MBL, Nagoya Japan), goat anti-integrin h 1 L-16 (Santa Cruz), rabbit anti-integrin h 1 pSer 785 (Biosource, Camarillo, CA), rabbit anti-p38MAPK (Cell Signaling, Beverly, MA), or rabbit anti-phospho-p38MAPK Thr 180 /Tyr 182 (Cell Signaling) antibodies. Proteins detected by these antibodies were visualized with horseradish peroxidase-conjugated anti-mouse (DAKOCytomation, Kyoto, Japan), rabbit (Bio-Rad, Hercules, CA), or goat (DAKOCytomation) antibody followed by the use of SuperSignal West Pico Stable Peroxidase Solution (Pierce).
In vivo experiments. Three-week-old female CB-17 SCID mice were purchased from Taconic Farms (Germantown, NY). The mice were kept in laminar flow rooms at constant temperature and humidity. They had free access to food and water. Experimental protocols were approved by the Institutional Ethics Committee for Animal Experimentation. Briefly, every A, following incubation with SB203580 at 6 (n) or 12 (.) hours, MTT assays were then done as described in Materials and Methods to determine cell viability. Points, mean of five separate experiments (n = 5); bars, SD. B, following incubation with SB203580 at 6 hours, plates were washed to discard nonadhesive cells and the number of adhesive cells remaining was quantified by MTT assay as described in Materials and Methods. Columns, mean of five separate experiments (n = 5); bars, SD. C, following incubation with SB203580 at 6 hours, levels of p38MAPK (p38 ) 
Results
Transfection of small interfering RNA against CD26 depletes its expression on Karpas 299 cells. Because CD26 surface expression is associated with aggressive disease in certain types of T-cell malignancies, including T-ALCL (9, 14), we evaluated the role of CD26 in the T-ALCL cell line Karpas 299, which expresses high level of CD26. To deplete CD26 expression, Karpas 299 cells (parent) were retrovirally transfected with siRNA against CD26. Two permanent transfectants were subsequently obtained and designated as CD26-depleted clone 1 (dep-1) and clone 2 (dep-2). The cells transfected with missense siRNA were used as controls (mock). Flow cytometry studies (Fig. 1A) and Western blotting analyses (Fig. 1B) indicate that CD26 expression is almost completely abrogated on CD26-depleted clones.
CD26 depletion is associated with decreased topoisomerase IIA level and decreased sensitivity to doxorubicin. We showed previously that transfectional overexpression of CD26 results in the up-regulation of topoisomerase IIa expression, associated with enhanced sensitivity to the topoisomerase II inhibitor doxorubicin (12, (15) (16) (17) . Consistent with our earlier work, our present studies clearly show that CD26 depletion results in decreased doxorubicin sensitivity (Fig. 1C) . Furthermore, we found that the expression of topoisomerase IIa as well as its phosphorylated active form (18) is down-regulated in CD26-depleted clones (Fig. 1D) . In contrast, the expression of other structures associated with doxorubicin sensitivity, such as lung resistance protein, multidrug resistance protein-1, and P-glycoprotein, is not influenced by CD26 depletion (data not shown).
CD26 regulates cell adhesion to extracellular matrix through phosphorylation of integrin B 1 . CD26 has been described previously to play a role in cell adhesion to the ECM under certain experimental conditions (1, 19) . Evaluating the potential effect of CD26 on tumor binding to the ECM, we found that parental Karpas 299 cells and mock clone display greater adhesion to the ECM proteins fibronectin and type I collagen I than CD26-depleted clones ( Fig. 2A) . Because integrins have a well-established role in cell adhesion to ECM proteins, we evaluated the potential association between CD26 and integrin h 1 , which is involved in cell adhesion to both fibronectin and collagen I (20) . We found that anti-integrin h 1 antibodies significantly block the adhesion of Karpas 299 cells to both fibronectin and collagen I as shown in Fig. 2B . Examining further the association between CD26 expression and integrin h 1 -dependent cell adhesion, we found no difference in the expression level of integrin h 1 among parental Karpas 299 cells, mock cells, and CD26-depleted clones by flow cytometry (data not shown) and Western blotting (Fig. 2C) . We next focused on the level of phosphorylated integrin h 1 at residue Ser 785 , which is necessary for integrin h 1 to function as an adhesion molecule (21) . Our findings showed that there is lower level of phosphorylation at integrin h 1 Ser 785 in CD26-depleted clones than in parental Karpas 299 and mock cells (Fig. 2C) .
p38MAPK intermediates between CD26 and integrin B 1 . We reported recently an association between CD26 and p38MAPK, with overexpression of CD26 resulting in increased p38 phosphorylation at Thr 180 /Tyr 182 and depletion of CD26 level leading to decreased p38 phosphorylation at the same residues (12). We therefore examined the possible relationship between p38MAPK and integrin h 1 using the p38MAPK-specific inhibitor SB203580. Although incubation of Karpas 299 cells with SB203580 for 6 hours up to a concentration of 40 Amol/L (Fig. 3A) does not lead to decreased cell viability, there is a dose-dependent inhibition of cell adhesion (Fig. 3B) . In addition, treatment with SB203580 is accompanied by a gradual dephosphorylation of integrin h 1 at Ser 785 as well as p38MAPK at Thr 180 /Tyr 182 (Fig. 3C ). Anti-CD26 antibody 202.36 inhibits cell adhesion with dephosphorylation of p38MAPK and integrin B 1 . To further delineate CD26 association with p38MAPK and integrin h 1 , we evaluated the effect of anti-CD26 binding on Karpas 299 cell adhesion to the ECM and p38MAPK and integrin h 1 phosphorylation. We found that the anti-CD26 antibody 202.36 suppresses adhesion of Karpas 299 cells, whereas antibodies recognizing other CD26 epitopes display no inhibitory effect on cell adhesion (Fig. 4A) . Of note is the fact that 202.36 does not affect cell viability at the dose and time tested (Fig. 4B) . Furthermore, the inhibitory effect is in a dose-dependent manner (Fig. 4C) . Importantly, we observed decreased phosphorylation of p38MAPK and integrin h 1 at the Thr 180 /Tyr 182 and Ser 785 residues, respectively, following treatment with the anti-CD26 antibody 202.36 (Fig. 5) .
CD26 depletion is associated with decreased tumorigenicity and increased survival in a severe combined immunodeficient mouse model. To investigate the effect of depletion of CD26 expression in an in vivo animal model, we inoculated mock and CD26-depleted clones into SCID mice i.p. and then monitored for tumor development and overall survival (Fig. 6) . All of the mice inoculated with mock Karpas 299 clones developed tumor masses in the inguinal areas. The largest palpable tumor mass was monitored by serial measurements, and all the mice with tumors were eventually sacrificed per protocol. Importantly, none of the mice inoculated with CD26-depleted clones developed tumor masses over the observed time. Similar studies done with CD26-depleted clone 2 also showed no tumor development over similar times tested (data not shown).
Discussion
In this article, we provide evidence linking CD26 to structures with important biological roles. We extend our previous studies by demonstrating the association between CD26 and topoisomerase IIa, with implications for the treatment of selected neoplasms with topoisomerase II inhibitors, such as doxorubicin. Importantly, our study is the first to report a linkage among CD26, p38MAPK, and integrin h 1 . Our data indicate that CD26 is associated with integrin-dependent adhesion of Karpas 299 cells to the ECM by regulating p38MAPK-dependent phosphorylation of integrin h 1 at Ser 785 . In addition, we show that down-regulation of CD26 expression decreases tumorigenicity of Karpas 299 cells in an in vivo SCID mouse xenograft model, hence suggesting that targeting CD26 may be an effective therapeutic strategy for selected neoplasms, specifically aggressive hematologic malignancies associated with high level of CD26 expression.
Previous work has suggested that CD26 may have a role in cell adhesion to ECM in selected experimental conditions (19, (22) (23) (24) , although the mechanism involved with CD26 role in cell adhesion has not been clearly elucidated. Our present findings indicate that (26, 27) . We also note that we consistently observe two bands on Western blotting with the particular antibody used to detect integrin h 1 phosphorylated at Ser 785 . Although the exact reason for this observation is presently unclear, several potential explanations can be offered. It is possible that particular breakdown products are detected along with the full-length protein. Alternatively, the level of phosphorylation at Ser 785 residues may differ for different integrin h 1 molecules, hence slightly altering the molecular weights of individual integrin h 1 molecule and resulting in the heterogeneous bands detected. It is also possible that variants of integrin h 1 exist in Karpas 299 cells that are phosphorylated at Ser 785 , leading to the observation of multiple protein bands.
Our data show that CD26 regulates integrin h 1 phosphorylation of Karpas 299 cells through its effect on p38MAPK. However, the mechanism involved in p38MAPK regulation of the phosphorylation status of integrin h 1 remains to be elucidated. Of note is the fact that transfectional overexpression of CD26 on the human Burkitt B-cell lymphoma cell line Jiyoye results in increased phosphorylation of p38MAPK (12) but does not lead to an accompanying enhancement in phosphorylation of integrin h 1 or induction of cell adhesion (data not shown). It is presently unclear how p38MAPK is able to induce phosphorylation of integrin h 1 in the T-cell lymphoma line Karpas 299 but not in the B-cell lymphoma line Jiyoye cells. It is likely that p38MAPK regulation of integrin h 1 phosphorylation is dependent on other factors that exist in the T-cell line Karpas 299 but not in the B-cell line Jiyoye. Likewise, it is presently unclear as to how CD26 regulates p38 phosphorylation. Given the fact that CD26 is a serine protease capable of cleaving selected biological factors, it is possible that CD26 indirectly regulates p38 phosphorylation pathway via the activity of its cleaved substrates. In addition, because CD26 physically and functionally associates with molecules with key roles in signal transduction, including the tyrosine phosphatase CD45 (5), CD26 may have an effect on p38 phosphorylation through its associated molecules.
An important aim of our present study is to clarify the role of CD26 in regulating the malignant behavior of tumors as a marker of aggressive disease for selected subsets for T-cell malignancies (9, 10, 14) , which may allow for the rational selection of CD26 as a potential target for novel therapy. Our in vivo data with SCID mouse xenografts conclusively show that depletion of CD26 expression on Karpas 299 cells results in loss of tumorigenicity and enhanced survival. It is likely that the inability to bind to the ECM as a result of CD26 depletion prevents tumor development in the animal model, given the fact that there is no difference in the rate of proliferation or the level of spontaneous cell death between CD26-positive and CD26-depleted Karpas 299 cells (data not shown). Given the fact that Karpas 299 is a T-ALCL cell line, it is interesting to note that in a study involving 8 cases of patients with T-ALCL, 5 of 8 (63%) cases were positive for CD26 expression (9) . Taken together, our findings suggest that CD26 ability to regulate cell adhesion through p38MAPK-dependent phosphorylation of integrin h 1 plays a key role in tumorigenicity of the T-ALCL cells Karpas 299 and that treatment strategies targeting CD26 may be an effective therapeutic approach for selected CD26-bearing tumors, including aggressive T-cell malignancies.
